Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Occurence of other malignancies in patients with CLL

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, gives an overview of a retrospective study investigating the occurrence of other malignancies in other patients with chronic lymphocytic leukemia (CLL). Dr Scarfò reports that chemoimmunotherapy increases the risk of acute myeloid leukemia and myelodysplasia, in particular with the combination of fludarabine, cyclophosphamide and rituximab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Lydia Scarfo, MD, has participated in advisory boards with AbbVie and Janssen and in educational activities with AstraZeneca.